10th Dec 2009 07:00
AGI Therapeutics Plc
("the Company")
Appointment of Nominated Adviser
AGI Therapeutics Plc (AIM, IEX: AGI), a speciality pharmaceutical development company announces that Davy has been appointed as the Company's Nominated Adviser with immediate effect.
Contact Information:
AGI Therapeutics plc.
Tel: +353 1 449 3254
David Kelly, Chief Financial Officer
Davy
John Frain
Tel: +353 1 679 6363
For further information please see www.agitherapeutics.com.
Notes to Editors:
About AGI Therapeutics plc
AGI is a specialty pharmaceutical company which is focused on the development and commercialisation of differentiated specialty drug products to treat unmet medical needs, including conditions which qualify for Orphan drug status.
The company has a portfolio of product candidates derived from its Known Molecular Entity (KME™) approach to drug re-profiling and development and aims to bring its products to the market either directly or through out-licensing or other partnering arrangements.
AGI's common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.
Related Shares:
Potentially Ai